Mumbai - Pharma major Lupin said it is in the process of setting up two new R&D centres in the US, focusing on research in inhalation and on complex formulations.
"In keeping with our global strategy of building a highly differentiated generic and speciality business, the company is in the process to setting up two dedicated Centres of Excellence for research in inhalation and complex injectables in Florida and Maryland in the US," Lupin chairman Desh Bandhu Gupta said in its annual report.
New Delhi: Drug firm Lupin Ltd has launched its generic Ciprofloxacin, used for treating bacterial infections, in the American market and is expecting 180 days of market exclusivity.
The company's US subsidiary, Lupin Pharmaceuticals Inc (LPI) has launched its Ciprofloxacin for oral suspension in the US market in the strengths of 5 g/100 mL (250mg/5 mL) and 10 g/100 mL (500 mg/5 mL), Lupin said in a statement.
The company had earlier received final approval for the product from the United States Food and Drug Administration (USFDA), it added.
Indian drug-maker Lupin Ltd on Monday reported better-than-expected third quarter net profit, and confirmed its latest acquisition - Nanomi B. V., which has patented technologies to develop complex injectable medicines.
The Asian country's No. 2 pharmaceutical firm by market value announced that its net profit grew 42 per cent year-on-year to Rs 4.8 billion in the October-December quarter of 2013. Analysts had projected the company's December quarter net profit at Rs 4.3 billion.
Mumbai, Oct 30 : Drug maker Lupin saw its consolidated net profit rising 39.8 percent in the second quarter to Rs. 406.20 crore, driven by other income, despite higher tax rate.
Consolidated revenue of the company grew 16 percent year-on-year (Y-o-Y) to Rs. 2,668 crore in quarter ended September 2013, supported by formulations business and strong growth US, Europe and Africa, the company said in a release.
Mumbai, Oct 3 : Drug maker Lupin Thursday said it has launched the generic version of Allergan Inc's Zymaxid Ophthalmic Solution in the US market with 180 days of marketing exclusivity.
Lupin Pharmaceuticals Inc, the company's US subsidiary, launched its generic Gatifloxacin Ophthalmic Solution 0.5 percent in the US market, after having received the regulator's final approval earlier, Lupin said in a statement.
Lupin stock extended its Thursday's gain of 1.89 per cent by gaining another 1.05 per cent to Rs 899.45 a share by mid of Friday, thanks to the announcement of the Mumbai-based company's strategic deal with MSD to co-market MSD's 23-valent Pneumococcal polysaccharide vaccine (PPV23) in India.
Drug maker, Lupin has said that it has obtained an approval from the health authorities in the US to sell its Suprax oral suspension, which is used to treat bacterial infections.
Lupin Pharmaceuticals Inc, a subsidiary of the drug maker, received an approval from the United States Food and Drugs Administration (USFDA) for selling Suprax for oral suspension in the strength of 500mg/5mL. The company is planning to begin exports to the US soon.
Mumbai-based Lupin Pharmaceuticals Ltd has launched a generic version of TriCor, which is a cholesterol lowering drug of Abbott Laboratories in the US market.
Lupin had received the approval from the US Food and Drug Administration for the generic version of the drug in December of the previous year. Lupin said in a statement said that the Tricor tablets have annual sales of $1.26 billion in the United States.
Lupin Limited is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world. Lupin was formed with the amalgamation of Lupin laboratories with Lupin Chemicals. Its activities include pharmaceuticals, bulk drugs and formulations, fermentation, bio-technology, natural products and agro chemicals.
The Indian pharma secondary sales (sales made by the distributor to chemists) facts for the month of April hints sturdy buoyancy in the market.
The value growth for the nation’s pharmaceutical market stayed strong for the third successive month, registering an increase of 18.2% during April.
Growth for the May last year to April this year period augmented to 16% from 15.2% growth in April 2011 to March 2012 period.
Pharmaceutical market research firm, AIOCD AWACS, accumulated the facts.
Research house Nirmal Bang has suggested buy call for Lupin with target price of Rs 633. Nirmal Bang has said in its research report dated 11, May 2012 that the results are in expectations.
The major issue was forex loss and the one-time tax on inventory sold to overseas subsidiaries of the company.
On Wednesday, the shares of Mumbai-based drug maker Lupin declined after the company revealed that billionaire Investor Rakesh Jhunjhunwala has sold his shares in the company worth more than Rs 300 crore in the first quarter.
The stock of lupin was traded at Rs 461.20 in the intra-day on the BSE, which was 3.7% less than its previous close.
INVESTMENT THESIS - Lupin is among the best players in the generic space given its strong execution capabilities and diversifying business model. To overcome volatilities in price erosion in the pure Vanilla Generic Segment, it has also built a formidable presence in the Branded Generic Segment.
• It has stellar supply-chain execution as it has garnered strong market share gains in the US in most major products, sometimes even from industry leaders like Teva and Sandoz. It is now the sixth-largest pharmaceutical company in the US by volume, indicating the trust it enjoys of major pharmacies and distributors.
Technical analyst Ashish Maheshwari of Global Capital Market is bullish on Lupin Limited and has maintained 'hold' rating on the stock.
According to the analyst, the interested investors can add more on dips of 5-7% from current levels.
Today, the stock of the company opened at Rs 389 on the Bombay Stock Exchange (BSE).
The share price has seen a 52-week high of Rs 519.80 and a low of Rs 317 on BSE.
Current EPS & P/E ratio stood at 19.19 and 20.06 respectively.
Lupin is one of the best plays in the pharma space, given its strong execution capabilities, improving financial performance and diversifying business model. The high-margin branded generic business has been the key differentiator. Strong growth on the US front (both branded generic and generic segments) and improvement in operating margins would maintain the growth momentum.
1) Strong traction in the high-margin Suprax product (chewable tablets approved; double strength tablets now enjoy more than 50% of total Suprax prescription share) and gradual pick up in Antara prescription.
Lupin Q3FY2011 results were in-line with estimates but single digit growth on US segment front was the disappointment. The management attributed this to inventory rationalisation in channels and change in accounting policy for rebates. Going ahead the company expects inventory in channels to pick-up to normal level. We recommend BUY on the stock with a target price of Rs537 valuing the stock at 22x FY2012E earnings. We believe the recent weakness in stock is a good entry point as long term drivers (OC launches in US, improvement of margins in Japan business, strong growth in India and other markets) are intact.
Indian groups appears to be under pressure to match steps with their Chinese competitors, divulges Boston Consultancy Group (BCG) review that picks out groups with ability to locate a position in the Fortune Global 500 association in the upcoming five years.
Just two Indian groups discovered a position in BCG's fourth version of the annual report on year's 100 "growing stars" of business through rising nations, as against 10 from China.
Technical analyst PK Agarwal of Purpleline Investment has maintained 'hold' rating on Lupin Limited stock with medium-to-long term view.
According to analyst, the investors can buy the stock with a stop loss of Rs 425.
Today, the stock of the company opened at Rs 468 on the Bombay Stock Exchange (BSE).
The share price has seen a 52-week high of Rs 519.80 and a low of Rs 277 on BSE.
Current EPS & P/E ratio stood at 17.78 and 25.48 respectively.
Stock market analyst MB Singh has maintained 'buy' rating on Lupin Ltd stock with a target of Rs 520.
According to analyst, the interested investors can buy the stock with a stop loss of Rs 482.
The stock of the company, on Nov 18, closed at Rs 492.90 on the Bombay Stock Exchange (BSE).
Current EPS & P/E ratio stood at 17.78 and 27.99 respectively.
The share price has seen a 52-week high of Rs 498 and a low of Rs 267 on BSE.
Stock market analyst Varun Daga has maintained 'buy' rating on Lupin Ltd stock to achieve a long term target of Rs 2010.
According to analyst, the interested investors can purchase the stock with stop loss of Rs 1785.
Today, the stock of the company opened at Rs 1881.25 on the Bombay Stock Exchange (BSE).
Current EPS & P/E ratio stood at 76.61 and 24.76 respectively.
The share price has seen a 52-week high of Rs 1970 and a low of Rs 780 on BSE.